Chapter 27.Quetiapine
Sections
Excerpt
Quetiapine is a second-generation antipsychotic (SGA) developed and subsequently marketed by AstraZeneca. In preclinical trials, quetiapine showed the features associated with antipsychotic efficacy, as well as a low rate of motor effects (Goldstein 1999; Nemeroff et al. 2002). Quetiapine was approved in 1997 by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia; it was subsequently approved in Europe and in other countries worldwide. Additional approvals and indications for quetiapine’s use in bipolar disorder, as well as approval of an extended-release formulation of quetiapine, have followed (Möller et al. 2007; Peuskens et al. 2007). The extended-release formulation has an additional indication as adjunctive treatment for major depression in patients who show inadequate response to antidepressants alone.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
